LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

Home・Elenco Azioni・Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

18.73 -4.15

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

18.56

Massimo

19.54

Metriche Chiave
By Trading Economics
Entrata	25M -43M
Vendite	-3.6M 65M
EPS	-0.48
Margine di Profitto	-65.788
Dipendenti	298
EBITDA	-16M -31M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+106.74% upside

Dividendi
By Dow Jones
Utili prossimi	3 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-77M 1.8B
Apertura precedente	22.88
Chiusura precedente	18.73

Notizie sul Sentiment di mercato

By Acuity

50%

153 / 344 Classifica in Healthcare

Syndax Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

1 giu 2026, 23:48 UTC

Discorsi di Mercato

Nikkei May Rise on Optimism Over AI Demand -- Market Talk

1 giu 2026, 23:38 UTC

Acquisizioni, Fusioni, Takeovers

Google Seeks $80 Billion for AI Buildout; Berkshire Will Buy $10 Billion Stake -- WSJ

1 giu 2026, 23:37 UTC

Discorsi di Mercato

Oil Edges Higher; Trump Seeks to Quell Israel-Hezbollah Conflict -- Market Talk

1 giu 2026, 23:01 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

1 giu 2026, 23:01 UTC

Discorsi di Mercato

Dexus Stuck in 'Too Hard' Basket -- Market Talk

1 giu 2026, 22:08 UTC

Acquisizioni, Fusioni, Takeovers

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

1 giu 2026, 22:01 UTC

Acquisizioni, Fusioni, Takeovers

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

1 giu 2026, 22:01 UTC

Acquisizioni, Fusioni, Takeovers

Google Seeks to Raise $80 Billion for AI Infrastructure -- Update

1 giu 2026, 21:55 UTC

Acquisizioni, Fusioni, Takeovers

Greg Abel's Week Is Off to Quite a Start -- WSJ

1 giu 2026, 21:53 UTC

Discorsi di Mercato

Strong Earnings Suppress Concerns About Oil Market -- Market Talk

1 giu 2026, 21:22 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

Berkshire's Abel Takes Big Swing With Back-to-Back Deals -- Market Talk

1 giu 2026, 20:50 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

Tech, Media & Telecom Roundup: Market Talk

1 giu 2026, 20:50 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

1 giu 2026, 20:50 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

1 giu 2026, 20:46 UTC

Acquisizioni, Fusioni, Takeovers

The Odds SpaceX Merges With Tesla Are Higher Than You Think -- Barrons.com

1 giu 2026, 20:22 UTC

Acquisizioni, Fusioni, Takeovers

Array Digital Infrastructure Doesn't Expect Additional Divs in 2026

1 giu 2026, 20:21 UTC

Acquisizioni, Fusioni, Takeovers

Array Digital Infrastructure Div Payable June 25 to Hldrs of Record June 11

1 giu 2026, 20:21 UTC

Acquisizioni, Fusioni, Takeovers

Array Digital Infrastructure Declares $11 Special Div

1 giu 2026, 20:20 UTC

Acquisizioni, Fusioni, Takeovers

Array Completes Sale of Select Spectrum Assets to Verizon for $1B

1 giu 2026, 19:40 UTC

Discorsi di Mercato

Remittances to Mexico Rise for Third Straight Month -- Market Talk

1 giu 2026, 19:28 UTC

Discorsi di Mercato

BoC Official Reiterates Need to Improve Business Investment -- Market Talk

1 giu 2026, 19:01 UTC

Discorsi di Mercato

Oil Futures Rise On Concerns About U.S.-Iran Talks -- Market Talk

1 giu 2026, 18:58 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Snap 3-Session Winning Streak -- Market Talk

1 giu 2026, 18:54 UTC

Acquisizioni, Fusioni, Takeovers

Berkshire Stock Drops. Its Bargain-Priced Deal for Home Builder Fails to Impress Investors. -- Barrons.com

1 giu 2026, 18:33 UTC

Discorsi di Mercato

Mexican PMIs Show Sluggish Manufacturing in May -- Market Talk

1 giu 2026, 18:32 UTC

Discorsi di Mercato

Precious Metals Fall to Start June -- Market Talk

1 giu 2026, 18:00 UTC

Acquisizioni, Fusioni, Takeovers

Marsh McLennan Agency Completes Acquisition Of TriBridge Partners >MRSH

1 giu 2026, 17:18 UTC

Discorsi di Mercato

Global Asset Managers Accumulate Canadian Government Debt -- Market Talk

1 giu 2026, 17:18 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

1 giu 2026, 17:10 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

Salesforce Estimated to Get $225M Sales Boost From Contentful -- Market Talk

Confronto tra pari

Modifica del prezzo

Syndax Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

106.74% in crescita

Previsioni per 12 mesi

Media 40.5 USD 106.74%

Alto 57 USD

Basso 29 USD

Basato su 11 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Syndax Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

11 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 11 che hanno fornito valutazioni azionarie a Syndax Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

153 / 344 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.